Shattuck Labs, Inc. STTK

STTK Company Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for cancer and immune-mediated diseases. The company operates within the biotechnology and immuno-oncology sectors and is primarily engaged in the discovery and development of engineered fusion protein therapeutics designed to modulate immune responses. Shattuck has historically centered its platform around bifunctional fusion proteins intended to improve immune activation while limiting toxicity associated with conventional immunotherapies.

The company’s primary value driver has been its clinical and preclinical pipeline, including programs targeting immune checkpoint and cytokine signaling pathways. Its lead development candidate has been SL-172154, an investigational therapy designed to combine CD47 blockade with SIRPα signaling modulation for hematologic malignancies. Shattuck was founded in 2016 and became publicly traded through a Nasdaq listing under the ticker STTK in 2020. Public filings and investor materials indicate the company has evolved from a broad platform-based immunotherapy developer toward a more focused oncology pipeline strategy following portfolio prioritization initiatives.